Biotechnology

Related Outside Content

While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on increased merger and acquisition activity. About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories (NYSE: ABT) agreeing to acquire St Jude Medical […]

Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, declined 17.0% […]

Expensive biologics have weighed on health care consumers. However, as the government tries to contain the soaring costs, a generic drugs-related exchange traded fund could capitalize on the growth of cheaper biosimilars. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which […]

The health care sector remains one of the worst performing areas of the market, despite the recovery off the Feb. 11 lows. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead. Based on […]

Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds that track the biotechnology sector surged as traders speculated that the two companies could court other merger targets. Biotechnology sector-related ETFs led gains on Wednesday. The BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), […]

As investors gear up for a volatile market in the year ahead, more aggressive exchange traded fund investors have utilized leveraged and inverse products to quickly adapt and capitalize on shifting market conditions. On the upcoming webcast, Tactical Strategies to Combat Market Volatility, Sylvia Jablonski, Managing Director and Co-Head of the Capital Markets & Institutional Strategy […]

Unloved ETF healthcare segment may provide a cheap opportunity for bargain hunters SPDR S&P 500 ETF (NYSEArca: SPY) is up 0.8% so far this year Investors may also be trying to catch a falling knife after the huge sell-off in the biotech sub-sector as biotechs remain in bear market territory Healthcare stocks, notably biotechnology names, […]

ETFs that implement derivative financial tools have drawn greater scrutiny from regulators Leveraged and inverse ETFs are being used as trading products over the short-term  Investors are taking both sides of the trade, or long bullish and short bearish positions during market turns Investors have utilized exchange traded funds that track leveraged and inverse strategies […]

Slow and steady value and conservative sectors are leading market gains RPV was best performing non-leveraged ETF across various Morningstar style categories  Close behind was RZV, which like RPV, targets companies exhibiting a value characteristic Since the start of the bull market, we may come to expect growth stocks like biotechnology and technology-sector exchange traded […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

The $3.5 billion First Trust Dorsey Wright Focus 5 ETF (NasdaqGM: FV) has helped exchange traded fund investors target some high-flying sectors, but the momentum strategy recently cut its biotech position for a defensive play. The First Trust Dorsey Wright Focus 5 ETF follows DWA’s relative strength ranking system where sector ETFs are compared to […]

While the broad U.S. equities market strengthened Thursday, the biotechnology sector looked under the weather, with sector-related exchange traded funds slipping to 52-week lows. On Thursday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) fell 3.6% and SPDR S&P Biotech ETF (NYSEArca: XBI) dropped 3.5%. Year-to-date, IBB declined 19.2% and XBI decreased 26.4%. Both biotech ETFs […]

Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for depressive disorder did not meet primary endpoints, Reuters reports. KMI shares plunged 42.3% Thursday, […]

We are heading into the earnings season, and investors are growing concerned over the outlook for biotechnology stocks and sector-related exchange traded funds as bellwether Celgene Corp. (NasdaqGS: CELG) expects weaker-than-expected growth last year. Biotech stocks were among the worst performers Monday, with the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and […]

After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December. Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%. The best performing non-leveraged ETFs over […]

Another acquisition deal in the biotechnology space for a rare disease specialist is fueling a jump in biotech stocks and sector-related exchange traded funds as traders hope further consolidation will help the industry maintain its momentum. Dublin-based Shire Plc (NasdaqGS: SHPG) has acquired U.S.-based Dyax Corp (NasdaqGM: DYAX) for about $5.9 billion, or potentially up […]

Investors interested in positioning their portfolios ahead of changes to major market trends may target specific market segments with sector-specific exchange traded funds. For instance, on the recent webcast, How Well Do Your Know Your Sectors?, David Mazza, V.P. and Head of Research at State Street Global Advisor, pointed out that the utilities sector was […]

U.S. prosecutors subpoenaed Valeant Pharmaceuticals International (NYSE: VRX), reinvigorating the drug pricing drama. However, the broader pharmaceutical space and sector-related exchange traded fund were shaking off the renewed pricing scrutiny Thursday as the industry rebounded along with the markets. The U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office sought information […]

With the advancements in biotechnology generating some attractive investment opportunities, exchange traded fund investors may now focus on a group of companies that specialize in the growing field of cancer immunotheraphy. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) began trading Wednesday, October 14, according to a press release. CNCR has a 0.79% expense ratio. “Immunotherapy […]

Exorbitant drug price concerns and a new Trans-Pacific Partnership deal sent biotech stocks and sector exchange traded funds reeling Tuesday. Biotech sector stocks were among the worst performing areas of the market Tuesday. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, dropped 3.4%, First Trust NYSE Arca Biotechnology Index Fund […]

Biotechnology stocks and related exchange traded funds gave back all of their gains this year and then some, and the sector may experience even more pain ahead. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, has declined over 10% since Friday and saw its worst day decline on a record […]

If you’re on team Hillary Clinton in the upcoming presidential election, you might want to trim down exposure to biotechnology stocks and sector-related exchange traded funds. “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on,” Democratic presidential candidate Hillary Clinton tweeted Monday, referring […]

The equities market and stock exchange traded funds jumped after the Federal Reserve announced it will be standing pat on record low U.S. interest rates for now in light of the weak economy, stubbornly low inflation and unstable global markets. Fed officials voted nine to one in favor of keeping current interest rates, stating Thursday […]

The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) lost another 1.1% yesterday. On its own, that does not sound like much, but the largest biotech exchange traded fund has lost ground in four of the past five sessions, a span in which IBB is off almost 4.7%. Some major biotech ETFs have been worse than IBB […]

As the Affordable Care Act adds millions into the healthcare system, the increased demand for health products and services are supporting the momentum in healthcare-related exchange traded funds. The healthcare sector has been among the best performing area in U.S. markets, with Health Care Select Sector SPDR (NYSEArca: XLV) up 12.0% and iShares U.S. Healthcare […]

The biotechnology sector and related exchange traded funds are breaking out to new highs, but the rapid ascension has some worried about valuations. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, has surged 27.9% year-to-date while the S&P 500 index has only gained 3.6%. However, given the lofty year-to-year returns, […]

Twenty-eight exchange traded funds hit all-time highs Wednesday. Underscoring the ongoing strength of the healthcare sector, 24 of those funds hailed from the healthcare sector. That is to say not that they need the help, but healthcare ETFs should be just fine if and when the Federal Reserve finally raises interest rates. “Health care firms […]

Ten biotechnology exchange traded funds hit all-time highs Wednesday, an impressive number when considering that represents about two-thirds of the biotech ETF universe. One of those 10 is also one of the group’s newest members, the BioShares Biotechnology Products Fund (NasdaqGM: BBP). Though off its highs of the day, BBP is still up 0.6%, extending […]

Biotechnology stocks and exchange traded funds have plenty of detractors that, primarily citing lofty valuations for an industry that is almost always richly valued relative to the broader market, think declines are on the way. Biotech ETFs also have plenty of supporters. That much is highlighted by today’s price action. To this point in Wednesday’s […]